Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

6.1%

5 terminated/withdrawn out of 82 trials

Success Rate

86.5%

-0.0% vs industry average

Late-Stage Pipeline

9%

7 trials in Phase 3/4

Results Transparency

19%

6 of 32 completed trials have results

Key Signals

16 recruiting6 with results

Enrollment Performance

Analytics

N/A
21(44.7%)
Phase 2
13(27.7%)
Phase 1
6(12.8%)
Phase 3
5(10.6%)
Phase 4
2(4.3%)
47Total
N/A(21)
Phase 2(13)
Phase 1(6)
Phase 3(5)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (82)

Showing 20 of 82 trials
NCT05220163Not ApplicableActive Not Recruiting

Evaluating the Impact of Computer-assisted X-ray Diagnosis and Other Triage Tools to Optimise Xpert Orientated Community-based Active Case Finding for TB and COVID-19

Role: collaborator

NCT05007795Not ApplicableNot Yet Recruiting

Test to Treat TB: Impact of Sputum Sequencing-guided Individualised Therapy on Outcomes in Drug-resistant Tuberculosis

Role: collaborator

NCT07479134Not ApplicableRecruiting

Production of Stem Cells for the Generation of Pancreatic Cells

Role: lead

NCT03392987Phase 2Completed

A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD)

Role: collaborator

NCT03512249Phase 2Completed

Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence

Role: collaborator

NCT06716853Phase 1Terminated

A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma

Role: collaborator

NCT06181994Recruiting

Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)

Role: collaborator

NCT04449406Recruiting

Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers

Role: collaborator

NCT06578845Recruiting

HappyMums Mobile Application Study

Role: collaborator

NCT01560182Phase 1Completed

Gene Therapy for Metachromatic Leukodystrophy (MLD)

Role: collaborator

NCT03837483Phase 3Active Not Recruiting

A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome

Role: collaborator

NCT04283227Phase 3Active Not Recruiting

OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD)

Role: collaborator

NCT04880317Not ApplicableTerminated

Validation of Quantitative Myocardial Tissue Characterization Through Non-gated CT

Role: collaborator

NCT05175794Completed

Triage Test for All Oral DR-TB Regimen (TRiAD Study)

Role: collaborator

NCT06318598Recruiting

Biomarker-driven Phenotypic Dissection of Amyotrophic Lateral Sclerosis

Role: collaborator

NCT03268135Recruiting

Heart Failure and Aortic Stenosis Transcriptome

Role: collaborator

NCT06922266Not Yet Recruiting

Personalizing Adoptive Cell Transfer for Solid Tumors: Towards a New Patient-tailored Treatment Option

Role: lead

NCT01515462Phase 1Completed

Gene Therapy for Wiskott-Aldrich Syndrome

Role: collaborator

NCT04568967Not ApplicableCompleted

TB-CAPT EXULTANT - HIV

Role: collaborator

NCT02800356Not ApplicableCompleted

Subthreshold Laser Treatment for Reticular Pseudodrusen and Geographic Atrophy Secondary to AMD

Role: lead